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The mechanisms of liver fibrosis progression and 
regression are mainly studied in experimental mouse 
models, which allow targeted interventions. Although it 
became evident from mouse models and human samples 
that restorative mechanisms are co-induced during 
ongoing injury as well, one of the key factors for tipping 
the balance towards fibrosis resolution is the cessation of 
chronic liver injury. While this is usually achieved in 
patients by successful suppression of hepatitis B or C 
virus replication or withdrawal from toxins such as alcohol 
[2], fibrosis regression is rapidly initiated in mouse models 
of fibrosis within days after termination of chronic injury 
such as toxin administration (e.g., carbon tetrachloride, 
thioacetamide), cholestasis (e.g., reversion of bile duct 
ligation) or metabolic challenge (e.g., methionine-choline 
deficient diet) [3]. Chronic injury is associated with the 
release of (pro-inflammatory) danger signals (e.g., 
HMGB-1, free DNA), activation of inflammatory signaling 
cascades in hepatocytes (e.g., NF-κB or JNK) and the 
release of manifold cytokines and chemokines, these 
processes cease upon termination of liver damage [4].
Recovering hepatocytes and their neighboring 
non-parenchymal cells switch the microenviron-
ment from a pro-inflammatory milieu to 
resolution, so that restorative and anti-inflamma-
tory mediators become dominant. As a 
consequence, the chemokine-mediated 
attraction of inflammatory monocytes (via 
CCR2) or NKT cells (via CXCL16) from the 
circulation but also the activation of intrahepatic 
and bypassing T cells is dramatically reduced 
[5], allowing the intrahepatic immune cells to 
adjust their phenotype. One of the most 
prominent phenotypic switches is observed for 
macrophages that acquire a restorative 
phenotype, characterized by low Ly6C 
expression in mice and high expression of 
matrix metalloproteinases (MMP), growth 
factors (favoring hepatocyte recovery) and 
phagocytosis-related receptors [6]. Interestingly, 
the phagocytosis of apoptotic myofibroblasts 
and/or hepatocytes might further promote the
The main collagen producing cells in the liver 
are hepatic stellate cells (HSC) that 
transdifferentiate into myofibroblasts [13]. The 
deactivation of myofibroblasts is key to fibrosis 
regression, and three mechanisms have been 
proposed: senescence, apoptosis and 
inactivation. Senescence describes a phenotype 
of myofibroblasts with reduced fibrogenic gene 
expression and cell cycle exit, which confers 
susceptibility to NK cell mediated apoptosis [14]. 
Driven by the withdrawal of anti-apoptotic 
signals as well as by NK, γδ T and possibly also 
CD8+ cytotoxic T cells, myofibroblasts undergo 
apoptosis during fibrosis regression [1,15]. 
Moreover, probably around half of the 
myofibroblasts become inactivated and revert to 
a “quiescent-like” HSC phenotype, but these 
inactivated HSC remain “primed”, meaning that 
they can more easily be reactivated to become 
myofibroblasts upon fibrogenic stimuli [16,17].
The ultimate step for achieving reversibility of 
fibrosis is the degradation of the excessive 
extracellular matrix. The most important 
degrading effectors are MMPs, which consist 
of a family of enzymes with different substrate 
affinities to matrix components [18]. Besides 
releasing anti-inflammatory mediators, 
restorative macrophages provide such 
fibrolytic mediators, especially MMP12 and 
MMP13 [6], but also neutrophils and HSC can 
express different MMPs [18]. However, some 
features of advanced fibrosis confer a relative 
resistance to matrix degradation; these 
features include collagen cross-linking and 
deposition of elastin [1].
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Liver fibrosis regression is also accompanied 
by increased numbers of dendritic cells (DCs) 
and NK cells in the liver [7]. While DCs favor 
matrix degradation via expression of MMP-9 
[7], NK cells induce the apoptosis of activated 
and senescent myofibroblasts via NKG2D and 
TRAIL [1,8]. In addition, gamma delta T cell 
receptor expressing T cells (γδ T cells) also 
induce myofibroblast apoptosis via Fas/FasL 
interactions [9].
Some recent studies provided new insights into 
the role of angiogenesis for fibrosis resolution. 
While angiogenesis is regularly observed in 
progressing fibrosis [10], sinusoidal 
angiogenesis might be a requirement for 
optimal fibrosis regression [11]. Pro-angiogenic 
factors like vascular endothelial growth factor 
(VEGF) or the chemokine CXCL9 from myeloid 
cells have been identified as important 
functional contributors to fibrosis resolution in 
mouse models [11,12].
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–Key facts
The successful treatment of chronic liver diseases such as viral hepatitis 
has provided compelling clinical evidence that liver fibrosis is, in principle, 
reversible. Mouse models of liver fibrosis regression are critical to define 
the essential cellular and molecular pathways for liver fibrosis resolution 
(see Figure).
Mechanisms of liver fibrosis resolution
The figure summarizes cellular and molecular mechanisms identified 
in animal models of liver fibrosis resolution. Important steps mediating 
the reversibility of liver fibrosis are the cessation of chronic damage 
(allowing hepatocyte recovery and modulating the microenvironment), 
shifting the balance from inflammation to resolution (leading to phenotypic 
adjustments of immune cells, especially induction of restorative 
macrophages), deactivation of myofibroblasts (by senescence, apoptosis 
and inactivation) and, finally, matrix degradation (reflected by an altered 
balance between matrix stabilizing and matrix degrading factors).
   Liver fibrosis is the typical response to chronic liver disease and 
characterized by the massive excess of extracellular matrix in the liver. 
Nowadays, liver fibrosis is viewed as an evolutionary conserved wound 
healing response to tissue injury, which is primarily driven by inflammatory 
and immune mediated mechanisms [1]. Importantly, liver fibrosis is not 
a unidirectional progressive process, ultimately leading to liver cirrhosis 
and organ failure, but is in principle reversible. A large body of clinical 
evidence, especially from patients effectively treated for chronic hepatitis 
B or C virus infections, suggest that regression from hepatic fibrosis 
occurs in liver disease patients, if the underlying liver injury is resolved 
or successfully treated [2]. This prompted intense basic research on the 
molecular and cellular mechanisms of liver fibrosis regression, intending 
to translate these findings into new therapies targeting such restorative 
pathways in human liver disease. These mechanisms can be roughly 
divided into four steps (see Figure), although we would like to emphasize 
that these pathways do not necessarily represent subsequent events but 
can be partially or fully activated also independent from each other.
Therapeutic targeting of fibrosis resolution
Understanding the cellular and molecular mechanisms of liver fibrosis 
regression prompted extensive research on new pharmacological 
approaches to augment these mechanisms. All of the above mentioned 
steps are currently investigated in preclinical and/or early clinical trials as 
potential targets (reviewed in [13,19]): (1) reduce or control tissue injury 
(e.g., by blocking apoptosis of hepatocytes); (2) transfer of bone-marrow 
derived restorative macrophages or inhibition of inflammatory monocyte 
infiltration (e.g., by blocking chemokine receptor CCR2 [cenicriviroc] or 
its ligand CCL2); (3) increase myofibroblast apoptosis (e.g., via CB1 
antagonist [rimonabant], 5HT antagonist or IFNγ directed to HSC); (4) 
increase matrix degradation by inhibiting the collagen cross-linking 
enzyme lysyl oxidase homologue 2 (e.g., via simtuzumab) or inhibiting 
TIMPs, the natural matrix metalloproteinase (MMP) antagonists. The rapid 
progress in understanding mechanisms of liver fibrosis resolution raises 
realistic hopes for effective antifibrotic therapies in the near future [13].
Conclusions
Important mechanisms for the reversibility of liver fibrosis are the cessation 
of chronic damage (allowing hepatocyte recovery and modulating the 
microenvironment), shifting the balance from inflammation to resolution 
(leading to phenotypic adjustments of the immune cells, especially 
induction of restorative macrophages), deactivation of myofibroblasts (by 
senescence, apoptosis and inactivation) and, finally, matrix degradation 
(reflected by an altered balance between matrix stabilizing and matrix 
degrading factors).
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